UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other ...

Bausch + Lomb (BLCO) reported $1.28 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 7.1%. EPS of $0.18 for the same period compares to $0.17 a year ago.The reported revenue represents a surprise of -0.04% over the Zacks Consensus Estimate of $1.28 billion. With the consensus EPS estimate being $0.16, the EPS surprise was +12.5%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determ ...

Core Insights - Bausch + Lomb (BLCO) reported quarterly earnings of $0.18 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and showing a slight increase from $0.17 per share a year ago, resulting in an earnings surprise of +12.50% [1] - The company posted revenues of $1.28 billion for the quarter ended September 2025, which was slightly below the Zacks Consensus Estimate by 0.04%, but an increase from $1.2 billion year-over-year [2] - Bausch + Lomb shares have underperformed the market, losing about 15.8% since the beginning of the year compared to the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.35 on revenues of $1.4 billion, and for the current fiscal year, it is $0.51 on revenues of $5.09 billion [7] - The estimate revisions trend for Bausch + Lomb was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Bausch + Lomb belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Bausch + Lomb (NYSE:BLCO) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsPatrick Wood - Managing DirectorSam Eldessouky - CFO and EVPTom Stephan - VP of Healthcare Equity ResearchYehia Hashad - Head of R&D and Chief Medical OfficerDavid Roman - Managing DirectorBrent Saunders - Chairman and CEOGeorge Gadkowski - VP and Head of Investor Relations and Business InsightsLily Lazada - VP of Equity ResearchJoanne Wuensch - Managing DirectorConference Call ParticipantsYoung Li - SVP and Equ ...

Bausch + Lomb (NYSE:BLCO) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsPatrick Wood - Managing DirectorSam Eldessouky - CFO and EVPTom Stephan - VP of Healthcare Equity ResearchYehia Hashad - Head of R&D and Chief Medical OfficerDavid Roman - Managing DirectorBrent Saunders - Chairman and CEOGeorge Gadkowski - VP and Head of Investor Relations and Business InsightsLily Lazada - VP of Equity ResearchJoanne Wuensch - Managing DirectorConference Call ParticipantsYoung Li - SVP and Equ ...

Bausch + Lomb (NYSE:BLCO) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Speaker4Good morning and welcome to Bausch + Lomb's third quarter 2025 earnings call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star ...

3Q25 Financial Results Forward-Looking Statements; Non-GAAP Information This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2025 full-year guidance), our strategic roadmap and the steps thereof, our antic ...

Exhibit 99.1 Bausch + Lomb Announces Third-Quarter 2025 Results VAUGHAN, Ontario, Oct. 29, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that continues to hum and steady introduction of innovative products across categories," said Brent Saunders, chairman and CEO, Bausch + Lom ...

Core Viewpoint - Activist investor Jana Partners has acquired a stake in The Cooper Companies and is advocating for strategic alternatives, including a potential merger of its contact-lens division with Bausch + Lomb [1][2] Group 1: Strategic Moves - Jana Partners aims to unlock shareholder value by improving capital allocation and possibly separating Cooper's two distinct business segments [2] - The CEO of Bausch + Lomb has expressed openness to a merger, suggesting it would enhance competition in the global contact-lens market [3][4] Group 2: Financial Performance - CooperCompanies has increased its share repurchase program by $1 billion to a total of $2 billion [1] - CooperVision's third-quarter sales reached $718.4 million, a 6% increase year-over-year, with fourth-quarter sales expected between $700 million and $713 million [7] - CooperSurgical sales rose by 4% to $341.9 million, with fourth-quarter expectations between $350 million and $356 million [8] Group 3: Market Context - Cooper is valued at approximately $14 billion, while Bausch + Lomb has a market capitalization of around $5.3 billion [4][5] - The contact-lens market is competitive, with major players including Cooper, Johnson & Johnson, and Alcon [5]

Bausch + Lomb is seen as a potential buyer for the contact-lens unit and the CEO said he would be interested. ...